BARDHI, ERLISA
 Distribuzione geografica
Continente #
NA - Nord America 498
EU - Europa 96
AS - Asia 69
AF - Africa 11
OC - Oceania 1
Totale 675
Nazione #
US - Stati Uniti d'America 495
IT - Italia 36
SG - Singapore 28
IN - India 21
SE - Svezia 18
CN - Cina 16
DE - Germania 11
TG - Togo 8
GB - Regno Unito 7
BG - Bulgaria 6
FI - Finlandia 6
BE - Belgio 3
CA - Canada 3
GR - Grecia 2
IR - Iran 2
MU - Mauritius 2
RO - Romania 2
UA - Ucraina 2
AU - Australia 1
CZ - Repubblica Ceca 1
ID - Indonesia 1
IE - Irlanda 1
KZ - Kazakistan 1
LT - Lituania 1
ZA - Sudafrica 1
Totale 675
Città #
Fairfield 94
Ashburn 61
Woodbridge 47
Seattle 37
Wilmington 32
Ann Arbor 29
Cambridge 28
Houston 25
Chandler 23
Singapore 19
Princeton 14
Beijing 13
Dearborn 11
Millbury 10
Bremen 8
Lomé 8
Rome 8
San Paolo di Civitate 7
Helsinki 6
Sofia 6
Lawrence 5
San Diego 5
Plano 4
Santa Clara 4
Boston 3
Brussels 3
Pomezia 3
Athens 2
Chicago 2
Kunming 2
Milan 2
Port Louis 2
Reggio Emilia 2
Toronto 2
Andover 1
Dallas 1
Des Moines 1
Dublin 1
Falls Church 1
Fremont 1
Hyderabad 1
Jacksonville 1
Jakarta 1
Kilburn 1
Mannheim 1
Muizenberg 1
Newcastle 1
Ottawa 1
Pathanamthitta 1
Phoenix 1
Prague 1
Ridder 1
Southend 1
Zhengzhou 1
Totale 547
Nome #
Rucaparib. An emerging parp inhibitor for treatment of recurrent ovarian cancer 123
Fertility preservation in ovarian tumours 91
Beyond circulating microRNA biomarkers. urinary microRNAs in ovarian and breast cancer 84
Non-compaction cardiomyopathy in pregnancy: a case report of spongy myocardium in both mother and foetus and systematic review of literature 66
Corrigendum to “Bartholin gland cancer” (Bartholin gland cancer (2017) 117 (1–11) 65
PI3K/AKT/mTOR pathway in ovarian cancer treatment: are we on the right track? 59
null 56
Management of morbidity associated with pancreatic resection during cytoreductive surgery for epithelial ovarian cancer: a systematic review 55
Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer. an updated meta-analysis of randomized clinical trials according to brca mutational status 32
null 30
Bartholin gland cancer 30
null 24
Etirinotecan pegol in women with recurrent platinum-resistant or refractory ovarian cancer. 12
Totale 727
Categoria #
all - tutte 1.879
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.879


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020183 0 0 0 3 20 29 30 27 32 22 15 5
2020/2021100 12 13 5 10 5 1 0 9 9 14 20 2
2021/2022113 0 5 12 10 13 5 3 12 5 11 15 22
2022/2023110 20 25 3 20 8 11 1 7 13 0 2 0
2023/202483 2 10 1 11 11 16 4 14 0 5 3 6
2024/202528 4 15 8 1 0 0 0 0 0 0 0 0
Totale 727